Citi analyst David Lebowitz upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Sell to Neutral with a price target of $36.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments Hot Upgrades Upgrades

Ionis Pharmaceuticals (IONS) PT Lowered to $37 at BarclaysMay 4, 2023 4:22 AM Form 10-Q IONIS PHARMACEUTICALS For: Mar 31May 3, 2023 4:29 PM Form 8-K IONIS PHARMACEUTICALS For: May 03May 3, 2023 11:16 AM Ionis Pharmaceuticals (IONS) Tops Q1 EPS by 4cMay 3, 2023 7:18 AM